Strategic Academia–Industry Partnership to Support U.S. Biosimilar Adoption

Challenge

A biopharmaceutical organization was preparing for the launch of one of the earliest biosimilar products in the United States during a period of significant regulatory and clinical uncertainty.

The central challenge was overcoming skepticism among regulators and clinical stakeholders regarding biosimilar comparability in the absence of traditional clinical efficacy data. In parallel, achieving support from treatment guideline committees required building confidence within the broader scientific and medical community.

Approach

A focused external engagement strategy was developed to address both regulatory and clinical adoption barriers simultaneously.

Key initiatives included:

• Distilling a highly complex scientific issue into a clear and accessible strategic narrative centered on a single question:
  “How similar is a biosimilar?”

• Identifying and engaging a carefully selected group of U.S. and European subject matter experts with deep experience in biologics, regulatory science, and evidence interpretation.

• Leveraging European clinical and regulatory experience to help contextualize biosimilar adoption for U.S. stakeholders and advisory committee discussions.

• Aligning scientific communication, expert advocacy, and stakeholder education around a consistent evidence-based framework.

Outcome

The strategy contributed to:

• Positive recommendation from a U.S. regulatory advisory committee.

• Inclusion within clinical treatment guidelines despite the absence of new comparative clinical efficacy trials.

• Increased confidence among key clinical and scientific stakeholders through credible expert engagement and scientific alignment.

Key Insight

Strategic selection and alignment of external experts can address multiple stakeholder challenges simultaneously — accelerating scientific acceptance, regulatory confidence, and clinical adoption.